Blurbs

Morphic Holding (MORF) Gets a Buy Rating from SVB Securities

In a report issued on August 3, Mike Kratky from SVB Securities reiterated a Buy rating on Morphic Holding (MORFResearch Report), with a price target of $45.00. The company’s shares closed last Thursday at $31.93.

According to TipRanks.com, Kratky is ranked #5708 out of 7991 analysts.

Currently, the analyst consensus on Morphic Holding is a Strong Buy with an average price target of $64.11, which is a 120.3% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $77.00 price target.

See today’s best-performing stocks on TipRanks >>

Morphic Holding’s market cap is currently $1.09B and has a P/E ratio of -19.98.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Read More on MORF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos